SCIENCE BRIEFING
Times Staff and Wire Reports
A prostate cancer vaccine produced by Dendreon Corp. of Seattle significantly improves survival, the company said Tuesday without releasing further details of the trial.
The trial was designed to detect a minimum 22% increase in survival, and experts speculate it did at least that well.
If the findings are upheld, the vaccine, called Provenge, could be the first cancer vaccine approved by the Food and Drug Administration.
Provenge is a so-called therapeutic vaccine designed to treat the disease.
